Company Active LTD

Company profile

Badrilla Limited

UK company 04809467, incorporated on 24 June 2003.

Home - Badrilla

Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.

Company number
04809467
Incorporated
24 Jun 2003
Companies House status
Active

Company identity

Founded / incorporated
24 June 2003

Company number 04809467

Verify at Companies House
Legal name
BADRILLA LIMITED
Company type
LTD
Region
Yorkshire and the Humber
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Jul 2023 to 30 Jun 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
6

Company events

Reference milestones and recent Companies House filing stream events.

1 event
24 Jun
2003

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2014
Funded years
2014, 2018
Age at first award
11 years

Projects

2018 Knowledge Transfer Partnership

The University of Liverpool and Badrilla Limited

1 Feb 2018 to 31 Jan 2020

Awarded
Unknown

To introduce and embed a new quantitative biomarker detection technique and develop products and services using this technology to enhance biomedical research and accelerate drug development by collaborators.

2014 GRD Proof of Market Lead participant

Market and product profiling for diagnostics in kidney injury

1 Dec 2014 to 30 Jun 2015

Awarded
£23,711
Total cost £39,519

Acute kidney injury (AKI) causes 12,000 preventable deaths per year in England. It affects 14% of people admitted to hospital, extending their hospital stay 2.5fold (£1.2Bn cost per annum to NHS England) and increasing their chance of death 4-5fold. Better diagnostics are required to identify AKI patients early. This will permit the focusing of resources ...

2014 Feasibility Studies Lead participant

Feature display diagnostics: A new approach for a new class of medical biomarker

1 Aug 2014 to 30 Nov 2014

Awarded
£24,750
Total cost £33,000

An emerging class of biomarkers important in medical diagnostics for cancer, dementia and cardiovascular disease is the chemical modification state of individual proteins. Quantitative diagnostic assays for these particular features of proteins are not available, and Badrilla proposes to develop an entirely new approach that will achieve such quantitative...

Product types

Feasibility Studies GRD Proof of Market Knowledge Transfer Partnership